SomnoMed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product desig… Read more
SomnoMed Limited (SOMNF) - Total Liabilities
Latest total liabilities as of June 2025: $34.58 Million USD
Based on the latest financial reports, SomnoMed Limited (SOMNF) has total liabilities worth $34.58 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SomnoMed Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how SomnoMed Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SomnoMed Limited Competitors by Total Liabilities
The table below lists competitors of SomnoMed Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kukje Pharma Co Ltd
KO:002720
|
Korea | ₩84.80 Billion |
|
Signature Alliance Group Berhad
KLSE:0360
|
Malaysia | RM193.24 Million |
|
First Bankers Trustshares Inc
OTCQB:FBTT
|
USA | $1.11 Billion |
|
Tifico Fiber Indonesia Tbk
JK:TFCO
|
Indonesia | Rp27.01 Million |
|
PRL Global Ltd
AU:PRG
|
Australia | AU$256.05 Million |
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
USA | $8.56 Million |
|
QS Energy Inc
PINK:QSEP
|
USA | $5.55 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down SomnoMed Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SomnoMed Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SomnoMed Limited (2004–2025)
The table below shows the annual total liabilities of SomnoMed Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $34.58 Million | +39.55% |
| 2024-06-30 | $24.78 Million | -38.18% |
| 2023-06-30 | $40.09 Million | +32.28% |
| 2022-06-30 | $30.31 Million | +26.23% |
| 2021-06-30 | $24.01 Million | -13.82% |
| 2020-06-30 | $27.86 Million | +64.54% |
| 2019-06-30 | $16.93 Million | +30.95% |
| 2018-06-30 | $12.93 Million | +26.05% |
| 2017-06-30 | $10.26 Million | +32.55% |
| 2016-06-30 | $7.74 Million | +23.96% |
| 2015-06-30 | $6.24 Million | -5.03% |
| 2014-06-30 | $6.57 Million | -2.32% |
| 2013-06-30 | $6.73 Million | +98.40% |
| 2012-06-30 | $3.39 Million | +34.87% |
| 2011-06-30 | $2.51 Million | +15.19% |
| 2010-06-30 | $2.18 Million | +28.06% |
| 2009-06-30 | $1.70 Million | +71.21% |
| 2008-06-30 | $995.73K | +26.76% |
| 2007-06-30 | $785.50K | -5.90% |
| 2006-06-30 | $834.72K | +16.53% |
| 2005-06-30 | $716.30K | -8.73% |
| 2004-06-30 | $784.78K | -- |